{"id":3700,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/artemether-with-lumefantrine-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"artemether-with-lumefantrine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/artemether-with-lumefantrine-txt\/","title":{"rendered":"Artemether with lumefantrine.txt"},"content":{"rendered":"

Artemether with lumefantrine<\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of malaria
\n

DOSE IN NORMAL RENAL FUNCTION <\/H3>
\n>35 kg: 6 doses of 4 tablets, i.e. 24 tablets
\ngiven over 60 hours
\nGive 4 tablets at 0, 8, 24, 36, 48 and 60 hours
\n

PHARMACOKINETICS <\/H3>
\n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nArtemether: 298.4;
    \nlumefantrine: 528.9\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nArtemether: 95.4;
    \nlumefantrine: 99.9\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \nNo data\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \nArtemether: 5.4\u20138.6;
    \nlumefantrine: 3.8\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \nArtemether 0.8\u20137;
    \nlumefantrine: 48\u201372
    \n(4\u20136 days in people
    \nwith falciparum
    \nmalaria)
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function.
    \nUse with caution
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min
    \n
  • HDF\/high flux &nbsp :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nUnknown dialysability. Dose as in
    \nnormal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Anti-arrhythmics: avoid concomitant use\n

    with amiodarone, disopyramide, flecainide
    \nand procainamide \u2013 risk of ventricular
    \narrhythmias
    \nAntibacterials: avoid concomitant use with <\/p>\n

    macrolides and quinolones. <\/p>\n

  • Antidepressants: avoid concomitant use\n
  • Antifungals: avoid concomitant use with\n

    imidazoles and triazoles.
    \nAntimalarials: increased risk of ventricular <\/p>\n

    arrhythmias with quinine \u2013 avoid
    \nconcomitant use. <\/p>\n

  • Antipsychotics: avoid concomitant use\n
  • Antivirals: avoid concomitant use with\n

    amprenavir, atazanavir, indinavir, lopinavir,
    \nnelfinavir, ritonavir and saquinavir;
    \npossibly increased risk of ventricular
    \narrhythmias with tipranavir \u2013 avoid
    \nconcomitant use
    \nBeta-blockers: avoid concomitant use with <\/p>\n

    metoprolol and sotalol<\/p>\n

  • Grapefruit juice: may increase\n

    bioavailability and inhibit metabolism \u2013
    \navoid concomitant use
    \nUlcer-healing drugs: avoid concomitant <\/p>\n

    use with cimetidine
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n\u2013
    \n

    Route <\/H4>
    \nOral<\/p>\n

    Rate of Administration <\/H4>
    \n\u2013
    \n

    Comments<\/H4>
    \nTake with food to increase absorption<\/p>\n

    If patient vomits within 1 hour of taking <\/p>\n

    the tablet the dose should be repeated
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • In renal impairment monitor ECG and\n

    potassium levels<\/p>\n

  • Undergoes extensive metabolism by the\n

    liver<\/p>\n","protected":false},"excerpt":{"rendered":"

    Artemether with lumefantrine CLINICAL USE Treatment of malaria DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3700","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3700"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3700\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}